Six of 10 Vacc!nes Investigated Found to Increase Mortality
As reported in “Vaccines — An Unresolved Story in Many Ways,”3 a new high titer measles vaccine rolled out in Africa in 1989 was found to double mortality from other diseases in girls. At first, the WHO refused to believe the results. The WHO didn’t withdraw the vaccine until 1992, after studies in Haiti, Sudan and other countries confirmed that female young children were dying in higher numbers.
During the 1990s, Stabell Benn and her colleague Peter Aaby continued studying the effect of many other vaccines on overall mortality, coming to the shocking conclusion that six of the 10 vaccines investigated actually INCREASED mortality by rendering children more susceptible to other lethal diseases.
The diphtheria, tetanus and pertussis (whooping cough) vaccine (DTP) had the same disastrous effect as the measles vaccine — it doubled mortality among children under the age of 5, and girls were again more likely to die.
Overall, live attenuated vaccines — the older measles vaccine, the bacillus Calmette-Gueri against tuberculosis, oral polio vaccine and the smallpox vaccine — all seemed to offer nonspecific protection against deadly diseases, contributing to lowering overall mortality.
Inactivated (non-live) vaccines, on the other hand — the DTP, pentavalent vaccine, inactivated polio vaccine, H1N1 influenza vaccine and the hepatitis B vaccine — increased overall mortality, especially among girls, even when they offered a high degree of protection against the target disease.
More recently, GlaxoSmithKline’s antimalarial vaccine (RTS, S/AS01 or RTS,S, sold under the brand name Mosquirix), which appears to offer between 18% to 36.3% protection against malaria depending on the age group,4 was also found to increase overall mortality.
As reported by “Vaccines — An Unresolved Story in Many Ways,” “Overall mortality was 24% higher among people who had been vaccinated against malaria compared with unvaccinated individuals.” Stabell Benn told Science News DK:5
“A vaccine that protects against malaria that does not reduce mortality makes no sense. We therefore asked GlaxoSmithKline for access to the original data and found that the vaccine reduced mortality among boys by a modest 15% while doubling the overall mortality rate for girls. This was the sixth non-live vaccine that we associated with mortality among girls — exactly as we had seen for other non-live vaccines.”
- 1, 3, 5, 6 Science News DK December 27, 2019
- 2 Clin Microbiol Infect. 2019 Dec;25(12):1459-1467
- 4 Lancet. 2015 Jul 4; 386(9988): 31–45
- 7, 8, 9 The BMJ 2020;368:l6920
- 10, 11 The BMJ 2020;368:m734
- 12 Clinicaltrials.gov, Malaria Vaccine Evaluation Programme
- 13 F1000 Research May 29, 2018
- 14, 22 Current Pharmaceutical Design 2013;19(8):1466-87
- 15 FDA.gov Gardasil Vaccine Safety
- 16 Journal of the Royal Society of Medicine January 21, 2020
- 17 Gardasil HPV Quadrivalent Vaccine May 18, 2006 VRBPAC Meeting (PDF) Page 13, “Concerns Regarding Primary Endpoint Analyses Among Subgroups”
- 18 Cancer Research UK January 22, 2020
- 19 Independent January 22, 2020
- 20 Children’s Health Defense January 23, 2020
- 21 Alabama News Center March 24, 2019
- 23 Scribd.com Rapporteurs’ Day 150 Joint Response Assessment Report: Gardasil 9
- 24 Kansas City Star September 26, 2018
- 25 Instagram Nickcatonemma February 25, 2020
- 26 Instagram Nickcatonemma February 26, 2020
No comments:
Post a Comment